

CD19, CD3E

Research Grade Duvortuxizumab

Catalog No.	DHD10808A DHD10808B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, JNJ-64052781, MGD011, RES192M1.2, CAS: 1831098-91-9		
Description:	Research Grade Duvortuxizumab is a bispecific chimeric humanized monoclonal antibody which targets B-lymphocyte antigen CD19 & T-cell surface glycoprotein CD3 epsilon chain		
UniProt ID (target):	P15391, P07766		
Specificity:	Human B-lymphocyte antigen CD19 & T-cell surface glycoprotein CD3 epsilon chain		
Source:	XtenCHO cell line		
Isotype:	Chimeric Human scFv-h-CH2-CH3(_scFv)_h-CH2-CH3		
INN:	Duvortuxizumab		
Concentration:	1.0 mg/ml, lot specific		
Formulation:	0.01M PBS, pH 7.4.		
Purity:	> 95% as determined by SDS-PAGE		
Purification:	Protein A/G affinity chromatography		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

